BPC-157 (Body Protective Compound 157, PL 14736) is a synthetic 15-amino-acid pentadecapeptide with a plasma half-life of approximately 15 minutes following subcutaneous administration in rat studies[1]. No published human pharmacokinetic study exists. Despite rapid plasma clearance, biological effects — including angiogenesis, tissue repair, and gut protection — persist for 24 hours or longer via downstream activation of VEGFR2, Akt-eNOS, ERK1/2, and FAK-paxillin signaling cascades[1]. This distinction between plasma half-life and biological effect duration is the defining pharmacological characteristic of BPC-157.
| Parameter | Value | Source |
|---|---|---|
| Plasma Half-Life (SC, rat) | ~15 minutes | Xu et al. 2022 [1] |
| Plasma Half-Life (IV, animal) | ~4–5 minutes (estimated) | Animal PK data [1] |
| Time to Peak (Tmax) — SC | ~15–30 minutes (animal) | Xu et al. 2022 [1] |
| Route(s) of Administration | SC injection, IM injection, Oral | — |
| Biological Effect Duration | 24–72+ hours | Signaling cascade data [1] |
| Full Plasma Clearance (5 half-lives) | ~75 minutes (animal estimate) | Calculated |
| Standard Research Protocol | 250–500 mcg SC once or twice daily | Community protocol |
| Data Quality | Animal Study — No published human PK data exists as of May 2026 | — |
BPC-157's plasma half-life of approximately 15 minutes is derived from a 2022 rat pharmacokinetic study by Xu et al. (PMC9794587)[1], which characterized subcutaneous absorption, plasma concentration curves, and tissue distribution in animal models. This is the primary peer-reviewed pharmacokinetic data set for BPC-157. No equivalent study has been conducted in humans, and no human PK data has been published in peer-reviewed literature as of May 2026.
The peptide's rapid plasma clearance is a direct consequence of its molecular structure: BPC-157 is an unmodified 15-amino-acid sequence with no albumin-binding modifications, no PEGylation, and no half-life extension technology. These structural features make it susceptible to rapid proteolytic degradation by circulating and tissue-bound peptidases, as well as renal filtration given its small molecular weight.
Plasma half-life is measured by tracking compound concentration in blood samples over time following administration. In the Xu et al. 2022 study[1], rats received subcutaneous BPC-157 injections, and serial blood samples were collected to construct a plasma concentration-time curve. The time required for plasma concentration to fall by 50% — the half-life — was approximately 15 minutes for the subcutaneous route.
For intravenous administration in animal models, clearance is estimated to be faster (approximately 4–5 minutes), as the compound enters systemic circulation directly without the absorption phase associated with subcutaneous injection. These estimates are consistent with the compound's structural properties but have not been independently confirmed in prospective human studies.
This is the most clinically and practically important concept in BPC-157 pharmacology, and it is widely misunderstood. BPC-157 has three entirely distinct pharmacological timescales, each measuring something different:
Layer 1 — Plasma Half-Life (~15 minutes, animal data): This measures how quickly the intact BPC-157 molecule disappears from the bloodstream. After approximately 75 minutes (5 half-lives), less than 3% of the original dose remains in plasma. This is a pharmacokinetic measurement of molecular presence, not of biological activity. It tells you when the peptide has left the blood — not when it stops working[1].
Layer 2 — Urine Detection Window (hours to ~24–48 hours, specialized assay): Specialized liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods have been developed and published to detect BPC-157 and its metabolic products in urine[2]. WADA has placed BPC-157 on its monitoring program. The detection window for BPC-157 using these specialized methods is estimated at hours to approximately 24–48 hours based on published forensic methods — substantially longer than plasma clearance because urine concentrates metabolites and peptide fragments. Standard workplace drug screens will not detect BPC-157; only purpose-built anti-doping assays can.
Layer 3 — Biological Effect Duration (24–72+ hours, signaling cascade data): Despite plasma clearance in under 2 hours, BPC-157's biological effects on tissue repair, angiogenesis, gut protection, and healing persist for 24 hours or longer. This is because BPC-157 activates receptor tyrosine kinases — specifically VEGFR2 — and initiates downstream signaling cascades (Akt-eNOS, ERK1/2, FAK-paxillin) that trigger transcriptional programs and structural cellular changes that outlast the peptide's presence in circulation[1]. The peptide is the trigger; the downstream cascade is the effect. These are distinct concepts: pharmacokinetics describes the molecule's fate in the body; pharmacodynamics describes what the molecule does to the body.
Based on the animal pharmacokinetic data from Xu et al. 2022[1], plasma clearance of BPC-157 following subcutaneous injection follows predictable first-order kinetics with an approximately 15-minute half-life:
| Half-Lives Elapsed | Time Post-Injection | % Remaining in Plasma |
|---|---|---|
| 1 | ~15 minutes | 50% |
| 2 | ~30 minutes | 25% |
| 3 | ~45 minutes | 12.5% |
| 4 | ~60 minutes | 6.25% |
| 5 (clinical clearance threshold) | ~75 minutes | ~3% |
Plasma clearance and biological effect duration are not the same measurement. BPC-157 reaches clinical plasma clearance (less than 3% of original concentration) within approximately 75 minutes of subcutaneous injection in rat models. However, the downstream signaling cascades activated by BPC-157 — VEGFR2 phosphorylation, Akt-eNOS pathway activation, ERK1/2 signaling, and FAK-paxillin cytoskeletal remodeling — continue to operate for hours to days after the peptide has left circulation[1]. This is the pharmacokinetic/pharmacodynamic disconnect that makes BPC-157 unique among repair peptides and explains why once-daily administration is standard despite the short plasma half-life.
The apparent paradox of BPC-157 — a 15-minute plasma half-life paired with once or twice daily dosing — is resolved by understanding the pharmacokinetic/pharmacodynamic distinction described above. Standard research protocols use 250–500 mcg subcutaneously once or twice daily not because continuous plasma presence is required, but because each injection initiates a new cascade of signaling events that sustain biological activity for 24 hours or longer. The injection is not maintaining a blood level; it is triggering a repair signaling program.
This mechanism is fundamentally different from drugs that require continuous receptor occupancy — such as many enzyme inhibitors or receptor antagonists — where plasma concentration directly determines magnitude of effect. BPC-157 operates more like a growth factor: brief engagement with its receptor triggers a prolonged downstream transcriptional and structural response.
BPC-157 is occasionally administered orally, particularly in research focused on gastrointestinal conditions including inflammatory bowel disease, gastric ulceration, and gut-brain axis modulation. Oral peptide administration typically raises concerns about enzymatic degradation in the gastrointestinal tract before systemic absorption, which would be expected to substantially reduce bioavailability for most peptides.
BPC-157 appears to have some resistance to gastric acid degradation in animal studies, which is one mechanistic rationale for exploring oral administration — particularly for locally acting effects in the gastrointestinal tract where systemic absorption may not be necessary for efficacy. However, no published human pharmacokinetic study has characterized oral bioavailability for BPC-157, and systemic bioavailability via oral route in humans remains unknown. For effects requiring systemic distribution (tendon repair, systemic angiogenesis), subcutaneous or intramuscular injection is the preferred route in research protocols.
| Compound | Plasma Half-Life | Data Source | Data Quality |
|---|---|---|---|
| BPC-157 | ~15 min (SC, rat) | Xu et al. 2022 [1] | Animal Study |
| TB-500 | Not formally published | — | Inferred — no published PK study |
| GHK-Cu (topical) | Minutes (estimated) | Structural analog data | Inferred |
| KPV | <30 min (estimated) | Animal data | Animal Study |
| Route | Half-Life | Bioavailability | Tmax | Notes |
|---|---|---|---|---|
| Subcutaneous | ~15 min (rat) | Unknown in humans | ~15–30 min (animal) | Most common research protocol |
| Intramuscular | No published data | No published data | No published data | Used in some research protocols |
| Intravenous | ~4–5 min (estimated) | 100% | Minutes | Reference route; rapid clearance |
| Oral | No published data | Potentially low (peptide degradation risk) | Unknown | Explored in GI repair research; some gastric acid resistance in animals |
BPC-157 is not detected by standard workplace urine drug screens, standard WADA anti-doping panels, or any broadly deployed drug testing platform. Standard immunoassay drug tests target specific controlled substance classes (opiates, amphetamines, cannabinoids, benzodiazepines, cocaine) and have no cross-reactivity with peptide compounds like BPC-157. Standard gas chromatography-mass spectrometry (GC-MS) confirmation panels used in occupational testing do not include BPC-157 in their target compound libraries.
WADA has placed BPC-157 on its monitoring program, indicating regulatory attention even in the absence of a full prohibition. Specialized liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection methods for BPC-157 in urine have been developed and published in the forensic and sports pharmacology literature[2]. These purpose-built assays can detect BPC-157 and related peptide fragments at trace concentrations.
The detection window using these specialized methods is estimated at hours to approximately 24–48 hours based on published detection methodology — longer than plasma clearance because urine concentrates metabolites over time. Competitive athletes subject to WADA testing or anti-doping programs should be aware that monitoring programs can transition to full prohibition lists, and the availability of published detection methods means that positive findings are technically feasible for anti-doping authorities with appropriate laboratory resources.
BPC-157's short plasma half-life is a direct consequence of its molecular structure. The compound is an unmodified 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a relatively small molecular weight. It carries no albumin-binding modifications (unlike semaglutide or liraglutide, which use fatty acid chains to extend half-life by binding to circulating albumin), no PEGylation (unlike some therapeutic proteins), and no cyclization or other structural stabilization. This means it is rapidly recognized and cleaved by circulating serum peptidases and tissue-bound proteases, and its small size also makes it subject to renal filtration[1]. The combination of proteolytic degradation and renal clearance produces the observed ~15-minute plasma half-life in animal models.
BPC-157's mechanism of action does not require sustained plasma presence because it operates through receptor activation rather than continuous receptor occupancy. After subcutaneous injection, BPC-157 engages vascular endothelial growth factor receptor 2 (VEGFR2) — a receptor tyrosine kinase — and activates the downstream Akt-eNOS signaling pathway, which promotes nitric oxide production, angiogenesis, and endothelial cell survival. Simultaneously, ERK1/2 (extracellular signal-regulated kinase 1/2) activation promotes cell proliferation and survival, while FAK-paxillin pathway engagement drives cytoskeletal reorganization critical for cell migration and tissue repair. These are not transient receptor occupancy effects; they are transcriptional and structural programs initiated by receptor engagement[1].
This explains the apparent paradox at the core of BPC-157 pharmacology: why a 15-minute plasma half-life produces 24–72 hours of biological effect. After the peptide binds VEGFR2 and activates the downstream cascade, gene expression changes, protein synthesis programs, and structural cellular remodeling processes are set in motion that proceed independently of the peptide's continued presence in plasma. This is analogous to how growth factors and cytokines function: a brief ligand-receptor interaction initiates a prolonged biological response. The distinction between pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body) is not merely academic — it is the key to understanding why standard BPC-157 protocols use once-daily dosing despite the molecule's rapid plasma clearance[1].
Log injection timing, dose, and site rotation on-device with no data shared externally.
Download on App StoreReal-time concentration model based on your actual dose and injection time. Free iOS app. On-device only.
Download on App Store